Skip to content
drillr.ai
Sign up

02186.HK

Luye Pharma Group Ltd.

HKSE · Healthcare · Drug Manufacturers - General · CN

HKD 1.90
+1.07%
Ask drillr

  • Sep 1, 2026, 09:11 UTC

    Shandong Commercial Group transferred 5% of Furuida's shares to Shandong State-owned Assets Investment Holding Co., Ltd., completing registration on August 31, 2026.

    Source:

  • Aug 30, 2026, 18:50 UTC

    Luye Pharma Group announced its interim results for the six months ended June 2026, with net profit of RMB 390 million, up 24.8% year-on-year, and revenue of RMB 3.002 billion, down 5.6%.

    Source:

  • Aug 20, 2026, 14:38 UTC

    Luye Pharma announced that its self-developed mRNA vaccine LY01620 will soon enter Phase II clinical trials in China for HPV16-positive high-grade cervical squamous intraepithelial lesions.

    Source:

  • Aug 5, 2026, 13:48 UTC

    Luye Pharma Group announced that its self-developed new molecular entity LY03015 has completed a bridging clinical trial in the United States, supporting its upcoming efficacy clinical trial in the United States.

    Source: